Athleticomed Sp. z o.o. — Clinical Trial Site

13 Registered trials

7 Currently recruiting

Organisation

Athleticomed Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100043492

Address

Ul. Fordonska 144, 85-752, Poland

Departments

Clinical trials at this site (13)

Search interface

Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag… Recruiting

2022-501099-24-00 Migraine 5 2023-12-22
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting

2022-501100-94-00 Episodic Migraine 5 2023-11-08
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Chronic migraine 5 2025-10-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Episodic migraine 5 2025-10-06
A Study to Assess the Adverse Events and Change in Disease Activity of Atogepant Oral Tablets in Pediatric Participants with Chronic Migrain… Recruiting

2024-513836-28-00 Chronic Migraine 5 2025-06-23
A study with eptinezumab in children and adolescents (6 to 17 years) with chronic or episodic migraine (REJOIN) Recruiting

2022-502917-27-00 Migraine 5 2023-03-07
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine (PROSPECT-2) Recruiting

2024-510656-13-00 Migraine 5 2022-11-08
AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTI… Ended

2023-505601-16-00 Chronic Migraine 5 2025-04-22
A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended

2024-512946-41-00 Menstrual Migraine 5 2025-03-05
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine Ended

2023-504930-23-00 Episodic Migraine 5 2019-07-19
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Witho… Ended

2023-510470-13-00 Overweight and Obesity 4 2023-03-10